期刊
JOURNAL OF CLINICAL MEDICINE
卷 10, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/jcm10040783
关键词
pneumonia; COVID-19; SARS-CoV2; anti-IL-6 drugs; HCQ
This article reviews drugs used in the treatment of COVID-19 patients, recommending the consideration of immunomodulatory drugs in severe cases, although clinical outcomes are still suboptimal. Early detection and treatment combined with a multidisciplinary approach may aid in better recovery of patients.
Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1 beta, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-alpha, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据